Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids.

We report the synthesis and biological activity of C-24 demethyl CDDO-Me 2 and the C-28 amide derivatives 3 and 4, which are analogues of the anti-inflammatory synthetic triterpenoid bardoxolone methyl (CDDO-Me) 1. Demethylation of the C-24 methyl group was accomplished via "abnormal Beckmann" rearrangement and subsequent ring A reformation. Amides 3 and 4 were found to be potent inhibitors of the production of the inflammatory mediator NO in vitro.

[1]  H. Griffiths,et al.  Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells , 2017, Free radical research.

[2]  Xu-Feng Huang,et al.  Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice , 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  K. Liby,et al.  CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages , 2016, PloS one.

[4]  M. Sporn,et al.  Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. , 2015, Carcinogenesis.

[5]  Xu-Feng Huang,et al.  Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl? , 2015, Journal of cardiac failure.

[6]  Shufeng Zhou,et al.  Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties , 2014, Drug design, development and therapy.

[7]  Xu-Feng Huang,et al.  The Endothelin Pathway: A Protective or Detrimental Target of Bardoxolone Methyl on Cardiac Function in Patients with Advanced Chronic Kidney Disease? , 2014, American Journal of Nephrology.

[8]  L. Fitzpatrick,et al.  The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice , 2014, Inflammopharmacology.

[9]  J. McMurray,et al.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. , 2013, The New England journal of medicine.

[10]  J. McMurray,et al.  Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  G. Gribble,et al.  Efficient and scalable synthesis of bardoxolone methyl (cddo-methyl ester). , 2013, Organic letters.

[12]  Masayuki Yamamoto,et al.  Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. , 2013, Antioxidants & redox signaling.

[13]  M. Sporn,et al.  Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease , 2012, Pharmacological Reviews.

[14]  M. Sporn,et al.  NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.

[15]  M. Konopleva,et al.  A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[16]  M. Sporn,et al.  Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis , 2011, Scientific reports.

[17]  Philip Raskin,et al.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes. , 2011, The New England journal of medicine.

[18]  M. Sporn,et al.  Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. , 2011, Free radical biology & medicine.

[19]  D. Graber,et al.  Synthetic Triterpenoid CDDO Derivatives Modulate Cytoprotective or Immunological Properties in Astrocytes, Neurons, and Microglia , 2011, Journal of Neuroimmune Pharmacology.

[20]  M. Sporn,et al.  New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress , 2011, Journal of natural products.

[21]  M. Sporn,et al.  Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer , 2010, Cancer Prevention Research.

[22]  M. Sporn,et al.  Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. , 2010, Free radical biology & medicine.

[23]  R. Peters,et al.  16-Aza-ent-beyerane and 16-Aza-ent-trachylobane: potent mechanism-based inhibitors of recombinant ent-kaurene synthase from Arabidopsis thaliana. , 2007, Journal of the American Chemical Society.

[24]  Jianwei Sun,et al.  Total synthesis of (−)-elegansidiol by using an abnormal Beckmann fragmentation of Hajos ketone oxime as a key step , 2007 .

[25]  M. Sporn,et al.  Platforms and networks in triterpenoid pharmacology , 2007 .

[26]  M. Sporn,et al.  Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer , 2007, Nature Reviews Cancer.

[27]  M. Sporn,et al.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. , 2007, Cancer research.

[28]  Neil J Ganem,et al.  2-Cyano-3,12-dioxooleana-1,9(11)-diene-28-oic Acid Disrupts Microtubule Polymerization: A Possible Mechanism Contributing to Apoptosis , 2006, Molecular Pharmacology.

[29]  M. Sporn,et al.  Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. , 2005, Bioorganic & medicinal chemistry letters.

[30]  M. Sporn,et al.  Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. , 2004, Journal of medicinal chemistry.

[31]  A. Wahhab,et al.  The synthesis of nor- and bisnorlupanes , 1991 .

[32]  F. Delbarre,et al.  The synthesis and bone resorbing activity of (25R)- and (25S)-26hydroxycholecalciferol (26-OH-D3). , 1978, Journal of steroid biochemistry.